Restructuring charges and a pending Xodus Medical deal headline a strong quarter.
STE STERIS plc
XNYS
257.12
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
STE
$257.12
—
What changed
Recent filings, trades and movesKey stats
$257.12
- 52-Week Range
- $195.14 – $269.44
- YTD
- +2.83%
- IV Rank (30D)
- 32.98
- Straddle Price
- $17.00
- P/C Vol Ratio
- 1.94
- Market Cap
- $25.0B
- Open
- $255.96
- Day Range
- $251.97 – $258.11
- Volume
- 934,238
- Prev Close
- $256.94
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 0.83 |
| Cost of Equity (CAPM) | 8.99% (VRP-adj) |
| WACC | 8.85% |
| Volatility Risk Premium | +21.8pp (IV − HV30) |
| Effective Tax Rate | 26.2% |
| Rev. Growth (YoY, DCF input) | +8.8% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.09 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.9B |
| Return on Equity (TTM) | 11.4% |
| Book / Price | 29.0% |
| Gross Margin (TTM) | 44.6% |
| FCF Margin (TTM) | 15.2% |
| Debt / Equity | 0.23 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +11.8% (reverse-DCF on current price) |
| SMA 50 | $221.04 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $231.88 |
| Bollinger Width / SMA20 | 19.9% (drives anchor stability) |
| Net Debt | $1.1B |
| Market Cap | $25B |
Peers used for multiples: ABT, BDX, BSX, GEHC, ISRG, MDT, RMD, SYK
60-Day Conviction
51%
20-Day Fair Value
≈ by Dec 9, 2026
$256.93
α -0.1%
rank 35%
conviction
6%
40-Day Fair Value
≈ by Jan 7, 2027
$253.47
α -1.4%
rank 35%
conviction
49%
60-Day Fair Value
≈ by Feb 5, 2027
$252.15
α -1.9%
rank 35%
conviction
51%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $213.50 | 24% | |
| DDM (Gordon) | $85.98 | 0% | |
| Peer P/E | $270.81 | 7% | median 29.6× · 8 peers |
| Peer EV/EBITDA | $280.85 | 7% | median 15.6× · 8 peers |
| Peer P/B | $258.53 | 7% | median 3.5× · 8 peers |
| Peer P/S | $254.97 | 7% | median 3.7× · 8 peers |
| Market Anchor (SMA50) | $221.04 | 24% | stability 51% (BB-width) |
| Options Expected (B-L 30d) | $258.83 | 24% | 21 strikes · skew +0.01 |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES (3842) · industry map
- Exchange
- XNYS
- Market Cap
- $25.0B
- Employees
- 17,937
- List Date
- 1992-06-02
- CIK
- 0001757898
- Last Earnings
- Nov 4 after close · +2.5% vs ±7.2% expected
- Next Earnings
- ~Feb 3, 2027 (estimated)
- Headquarters
- Dublin, L2
- Homepage
- https://www.steris.com
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Se…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -0.73% | -7.49% | 11.28% | 0.86% | 8.98% | 5.02% | 2.99% |
| Feb | -6.18% | 6.36% | -12.34% | 4.16% | 0.42% | -4.50% | -2.01% |
| Mar | 7.15% | 1.90% | 1.46% | -3.42% | 1.76% | -10.75% | -0.32% |
| Apr | 9.05% | -9.66% | -1.03% | -7.45% | -0.43% | -1.39% | -1.82% |
| May | -10.59% | 1.85% | 4.09% | 8.70% | 10.34% | -0.78% | 2.27% |
| Jun | 9.48% | -6.91% | 11.15% | -3.87% | -0.77% | -0.24% | 1.47% |
| Jul | 4.31% | 6.96% | 2.93% | 9.25% | -6.66% | 7.57% | 4.06% |
| Aug | -1.52% | -9.50% | 2.49% | 0.04% | 8.02% | 0.00% | -0.08% |
| Sep | -5.94% | -16.95% | -4.96% | -0.25% | 2.24% | -8.55% | -5.73% |
| Oct | 12.59% | 1.48% | -2.56% | -5.91% | -2.32% | 8.49% | 1.96% |
| Nov | -7.32% | 7.44% | -5.64% | -2.72% | 12.20% | 10.19%* | 2.36% |
| Dec | 12.88% | -3.96% | 8.03% | -6.08% | -3.56% | -- | 1.46% |
| Total | 21.24% | -27.71% | 12.86% | -8.04% | 32.28% | 2.75% | 5.56% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $233.85
SMA 50: $221.53
SMA 200: $224.19
Current: $257.12
EMA 12: $242.96
EMA 26: $233.52
MACD: 9.4445 | Signal: 2.8848
BULLISH
ADX (14): 39.88
TREND
+DI: 38.30
−DI: 8.17
Momentum Oscillators
RSI (14): 75.44
OVERBOUGHT
Stoch %K: 90.03
Stoch %D: 88.57
Williams %R: -5.72
Volume & Volatility
BB Upper: $258.40
BB Lower: $209.30
NEUTRAL
OBV: 3,017,830
Vol SMA 20: 864,858
Vol ROC: 78.71%
ATR: $6.74
True Range: $6.14
HV 20: 36.1%
HV 30: 31.0%
HV 60: 26.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before STE’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
SYMBOL: STE
Executive Summary BULLISH (Confidence Level: 7/10)
Key drivers:
- Bullish MACD signal
- Trend support from SMAs
- Low volatility and risk profile
Primary risks:
- Overbought RSI reading
- Potential breakdown below SMA 200 support
Investment thesis: STERIS is likely to continue its uptrend, driven by technical momentum and low volatility. However, caution should be exercised due to the overbought RSI reading and potential breakdown risk.
Recent news sentiment impact: The recent news headlines have been neutral, with no significant market-moving events or surprises that could significantly impact the stock's price.
Technical Analysis Trend Direction: Short-term (1-4 weeks) - Bullish
Support/Resistance Levels:
- SMA 200: $234.24
- Middle Bollinger Band: $226.33
- Lower Bollinger Band: $206.73
Momentum Signals: RSI interpretation: Overbought (>70), potential sell signal MACD signal: Bullish (crossover above signal line) Bollinger Bands position: Neutral (price touching middle band)
Volume Analysis: Volume SMA 20: 669527.20 On-Balance Volume (OBV): 10494926.28 Volume Rate of Change: -62.82%
News & Sentiment Analysis Recent Headlines Summary:
- STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026 (GlobeNewswire Inc., 2026-07-27) - Neutral sentiment
- STERIS Announces Dividend of $0.63 per share (Benzinga, 2026-05-05) - Positive sentiment
- CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors (GlobeNewswire Inc., 2025-12-23) - Neutral sentiment
Sentiment Assessment: Neutral overall, with a slight positive bias due to the dividend announcements.
Catalyst Identification:
- Upcoming conference call on August 6, 2026
- Earnings release for Fiscal 2027 First Quarter (date not specified)
Market Narrative: The recent news headlines have been neutral, but the upcoming conference call and earnings release could provide catalysts for price movement. The technical signals suggest a bullish trend, while the low volatility suggests a high degree of confidence in the stock's price.
Risk & Volatility Assessment Beta Interpretation: Low risk relative to market (beta = 0.46)
Volatility Regime: Current vs historical volatility levels - Low volatility
Options Market Signals:
- IV Rank: 18.3% (Low)
- Current IV: 38.9%
- Expected Move: $13.05 (35 DTE), 7-DTE: $7.03
- Volume Flow: 78 calls vs 72 puts
- Open Interest: 385 calls vs 134 puts
- Put/Call Volume Ratio: 0.92 (Neutral sentiment)
- Put/Call OI Ratio: 0.35
Downside Protection: Support levels and risk management considerations - SMA 200 support at $234.24, with a potential stop-loss level at this price.
Market Context & Positioning Sector Performance: Relative strength vs sector/market - Neutral
Institutional Activity: Volume patterns suggesting institutional interest - Moderate volume flow
Correlation Analysis:
- Stock moves relatively less than market (R-squared interpretation)
- Strong correlation between stock and SPY (0.23)
Relative Valuation: Position within trading range - Mid-range, with a potential breakout above SMA 200 support.
Key Levels & Action Items Critical Price Levels:
- Support: $234.24 (SMA 200)
- Resistance: $245.92 (Upper Bollinger Band)
Breakout/Breakdown Levels:
- Breakout above SMA 200 support ($234.24) could trigger a strong uptrend
- Breakdown below SMA 200 support could lead to further downside pressure
Time-Sensitive Catalysts:
- Upcoming conference call on August 6, 2026
- Earnings release for Fiscal 2027 First Quarter (date not specified)
Risk Management: Stop-loss level at $234.24 (SMA 200 support), with a potential target price of $245.92 (Upper Bollinger Band).
Conclusion STERIS is likely to continue its uptrend, driven by technical momentum and low volatility. However, caution should be exercised due to the overbought RSI reading and potential breakdown risk. The upcoming conference call and earnings release could provide catalysts for price movement.
Generated
News
All STE news →
Earnings History
17 of 24 under expected move
Avg Expected Move
6.52%
Avg Actual Move
4.82%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-02 | After-Close | 4.50% | 4.30% | 0.96x | Within |
| 2021-04-27 | After-Close | 10.03% | 0.73% | 0.07x | Within |
| 2021-08-09 | After-Close | 4.88% | 1.21% | 0.25x | Within |
| 2021-11-02 | After-Close | 9.25% | 5.92% | 0.64x | Within |
| 2022-02-08 | After-Close | 5.03% | 2.89% | 0.57x | Within |
| 2022-05-12 | After-Close | 3.66% | 1.01% | 0.28x | Within |
| 2022-08-02 | After-Close | 2.14% | 9.55% | 4.46x | Exceeded |
| 2022-11-09 | After-Close | 8.08% | 5.15% | 0.64x | Within |
| 2023-02-08 | After-Close | 6.02% | 10.89% | 1.81x | Exceeded |
| 2023-05-10 | After-Close | 7.68% | 9.83% | 1.28x | Exceeded |
| 2023-08-01 | After-Close | 6.90% | 1.69% | 0.24x | Within |
| 2023-11-07 | After-Close | 5.82% | 5.46% | 0.94x | Within |
| 2024-02-07 | After-Close | 7.61% | 2.48% | 0.33x | Within |
| 2024-05-08 | After-Close | 6.35% | 7.57% | 1.19x | Exceeded |
| 2024-08-06 | After-Close | 10.78% | 2.36% | 0.22x | Within |
| 2024-11-06 | After-Close | 5.71% | 5.28% | 0.92x | Within |
| 2025-02-05 | After-Close | 5.89% | 2.09% | 0.35x | Within |
| 2025-05-14 | After-Close | 6.09% | 8.52% | 1.40x | Exceeded |
| 2025-08-06 | After-Close | 5.99% | 6.79% | 1.13x | Exceeded |
| 2025-11-05 | After-Close | 7.07% | 6.94% | 0.98x | Within |
| 2026-02-04 | After-Close | 7.06% | 7.74% | 1.10x | Exceeded |
| 2026-05-11 | After-Close | 5.97% | 4.46% | 0.75x | Within |
| 2026-08-05 | After-Close | 6.79% | 0.40% | 0.06x | Within |
| 2026-11-04 | After-Close | 7.18% | 2.50% | 0.35x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
STE Options Activity & IV Rank
STE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 26.0%
7-DTE IV: 30.0%
Expected Move: $17.00
7-DTE Move: $10.47
Days to Exp: 38 (2026-12-18)
Options Flow · All expiries
Call Volume: 113
Put Volume: 219
P/C Volume: 1.938
BEARISH
Call OI: 1,745
Put OI: 1,661
P/C OI: 0.952
Total OI: 3,406
ATM Options Pricing
ATM Call: $7.10
ATM Put: $9.90
Call %: 2.8%
Put %: 3.9%
Chain Summary
Chain Volume: 332
Chain OI: 3,406
Last Updated: 11/10/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 90th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
90%
vs own history
GEX tilt
+0.61
OI-weighted, today
Vanna tilt
+0.75
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.75: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 14 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)18.9LowNov 10
IV Rank (30 DTE)33.0MediumNov 10
Straddle Price (30 DTE)$17.00Nov 10
Beta Analysis
Risk Metrics
Beta: 0.4221
Alpha: -3.65%
Correlation: 0.2188
R-Squared: 4.8%
Stock Volatility: 26.4%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own STE
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $85.1M | #467 of 6285 | +268.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $48.2M | #634 of 3716 | +802.9% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $24.4M | #616 of 3138 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2.7M | #1236 of 4729 | -1.8% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $2.1M | #707 of 997 | -11.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
STE Institutional Ownership (13F)
Filings for 2026-06-30 · 392 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 98,175,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$11.30M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Twin Tree Management, LP | $3.54M | 31.30% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $3.33M | 29.43% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $1.74M | 15.42% | 2026-09-30 |
| 4 | Susquehanna International Group, LLP Custodian | $1.62M | 14.34% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $1.05M | 9.31% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $21.00K | 0.19% | 2026-09-30 |
5 filers$2.46M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Twin Tree Management, LP | $1.24M | 50.44% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $568.54K | 23.08% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $421.14K | 17.10% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $210.01K | 8.53% | 2026-09-30 |
| 5 | Simplex Trading, LLC Custodian | $21.00K | 0.85% | 2026-09-30 |
STE Insider Trading (Form 4)
Latest: 2026-10-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Karen L Burton | Sr. Vice Pres., CFO | Tax (F) | −228 | — | EDGAR | |
| 2026-08-12 | Christopher S Holland | Director | Grant (A) | +1,025 RSU | — | EDGAR | |
| 2026-08-12 | Paul Edward Martin | Director | Grant (A) | +2,018 RSU | — | EDGAR | |
| 2026-08-12 | Esther M. Alegria | Director | Grant (A) | +2,018 opt | — | EDGAR | |
| 2026-08-12 | Cynthia L Feldmann | Director | Grant (A) | +2,018 RSU | — | EDGAR | |
| 2026-08-12 | Mohsen Sohi | Director | Mixed Sell −4,058 · Exer +4,058 |
— | $161.00 | -$606.9K | EDGAR |
| 2026-08-12 | Nirav R Shah | Director | Grant (A) | +2,018 RSU | — | EDGAR | |
| 2026-08-12 | Pierre Boulud | Director | Grant (A) | +1,025 RSU | — | EDGAR | |
| 2026-08-12 | Louis Shapiro | Director | Grant (A) | +1,025 RSU | — | EDGAR | |
| 2026-07-02 | Mohsen Sohi | Director | Mixed Exer +3,781 · Tax −1,837 |
+1,944 | $117.47 | -$120.0K | EDGAR |
| 2026-06-16 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | Sell (S) | −1,419 | $209.28 | -$297.0K | EDGAR |
| 2026-06-08 | Mary Clare Fraser | SVP & Chief HRO | Tax (F) | −600 | $212.24 | -$127.3K | EDGAR |
| 2026-06-08 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | Tax (F) | −401 | $212.24 | -$85.1K | EDGAR |
| 2026-06-08 | Renato Tamaro | V.P. & Corporate Treasurer | Tax (F) | −65 | $212.24 | -$13.8K | EDGAR |
| 2026-06-08 | Kenneth E Kohler | SVP & GM, AST | Tax (F) | −150 | $212.24 | -$31.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
STE Insider Holdings
15 insiders · @ $257.12
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel A Carestio | President and CEO | 68,075 | $17.50M | -$14.87M | 45 | 2026-06-08 |
| 2 | Richard C Breeden | Director | 67,687 | $17.40M | -$10.32M | 48 | 2026-06-04 |
| 3 | Michael J Tokich | Sr. Vice Pres., CFO | 47,483 | $12.21M | -$50.91M | 59 | 2025-06-06 |
| 4 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | 35,259 | $9.07M | -$12.80M | 56 | 2026-06-16 |
| 5 | Mohsen Sohi | Director | 28,363 | $7.29M | -$5.86M | 39 | 2026-08-12 |
| 6 | Cary L Majors | SVP and President, Healthcare | 17,472 | $4.49M | -$10.59M | 29 | 2026-06-04 |
| 7 | Mary Clare Fraser | SVP & Chief HRO | 13,716 | $3.53M | $0 | 16 | 2026-06-08 |
| 8 | Karen L Burton | Sr. Vice Pres., CFO | 12,956 | $3.33M | -$8.17M | 46 | 2026-10-05 |
| 9 | Cynthia L Feldmann | Director | 12,466 | $3.21M | -$6.40M | 39 | 2026-08-12 |
| 10 | Julia Madsen | Sr. VP and GM, Life Sciences | 12,257 | $3.15M | -$3.14M | 30 | 2026-06-08 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
STE Board & Officers
As of SEC filings through Oct 5, 2026Directors 9
- Cynthia L Feldmann · since Mar 28, 2019
- Mohsen Sohi · since Mar 28, 2019
- Nirav R Shah · since Mar 28, 2019
- Christopher S Holland · since Jul 28, 2020
- Paul Edward Martin · since May 5, 2021
- Daniel A Carestio · listed since Jun 2022
- Esther M. Alegria · since May 3, 2023
- Louis Shapiro · since Jul 31, 2025
- Pierre Boulud · since May 5, 2026
Officers 9
- Daniel A Carestio · President and CEO · listed since Jun 2022
- Cary L Majors · SVP and President, Healthcare · listed since Dec 2022
- Karen L Burton · Sr. Vice Pres., CFO · listed since Oct 2025
- Mary Clare Fraser · SVP & Chief HRO · listed since Jun 2022
- John Adam Zangerle · Sr. VP, Gen Counsel, and Sec. · since Mar 27, 2019
- Renato Tamaro · V.P. & Corporate Treasurer · since Mar 28, 2019
- Kenneth E Kohler · SVP & Gm, Ast · since Feb 22, 2024
- Julia Madsen · Sr. VP and GM, Life Sciences · listed since Oct 2024
- Lindsey McGowan · VP, Chf. Comp. & Quality Offc. · since Jan 1, 2026
Changes in the last 10 years (49)
| May 5, 2026 | Pierre Boulud became a director |
| May 1, 2026 | The company announced the departure of Richard C Breeden from the board in an SEC filing |
| Jan 1, 2026 | Lindsey McGowan became VP, Chf. Comp. & Quality Offc. |
| Oct 3, 2025 | Karen L Burton listed as Sr. Vice Pres., CFO (previously VP & CAO) in SEC filings |
| Jul 31, 2025 | The company announced the departure of Michael J Tokich as Sr. Vice Pres., CFO in an SEC filing |
| Jul 31, 2025 | Louis Shapiro became a director |
| Jul 1, 2025 | The company announced the departure of Richard Martin Steeves from the board in an SEC filing |
| Oct 2, 2024 | Julia Madsen listed as Sr. VP and GM, Life Sciences (previously Senior VP, Life Sciences) in SEC filings |
| Jun 4, 2024 | Andrew Xilas reported in an SEC filing no longer being SVP and GM, Dental |
| May 16, 2024 | Karen L Burton listed as VP & CAO (previously VP, Controller & CAO) in SEC filings |
| Feb 22, 2024 | Kenneth E Kohler became SVP & Gm, Ast |
| May 3, 2023 | Esther M. Alegria became a director |
| Dec 5, 2022 | Cary L Majors listed as SVP and President, Healthcare (previously Sr VP Americas Com Operations) in SEC filings |
| Jun 3, 2022 | Mary Clare Fraser listed as SVP & Chief HRO (previously Vice President & Chief HRO) in SEC filings |
| Jun 2, 2022 | Daniel A Carestio listed as President and CEO (previously Sr VP and Chief Operating Off) in SEC filings |
| Jun 2, 2022 | Daniel A Carestio first listed as a director in an SEC filing |
| Jun 2, 2022 | Cary L Majors listed as Sr VP Americas Com Operations (previously Sr VP N America Com Operations) in SEC filings |
| Jun 2, 2021 | Andrew Xilas became SVP and GM, Dental |
| May 5, 2021 | Paul Edward Martin became a director |
| Jul 28, 2020 | Julia Madsen became Senior VP, Life Sciences |
| Jul 28, 2020 | Christopher S Holland became a director |
| Jul 20, 2020 | Mary Clare Fraser became Vice President & Chief HRO |
| Oct 2, 2019 | Cary L Majors listed as Sr VP N America Com Operations (previously VP, N America Com Operations) in SEC filings |
| May 7, 2019 | Cary L Majors became VP, N America Com Operations |
| Mar 28, 2019 | Walter M Rosebrough Jr first listed as a director in an SEC filing |
| Mar 28, 2019 | Richard Martin Steeves became a director |
| Mar 28, 2019 | Richard C Breeden became a director |
| Mar 28, 2019 | Renato Tamaro became V.P. & Corporate Treasurer |
| Mar 28, 2019 | Nirav R Shah became a director |
| Mar 28, 2019 | Mohsen Sohi became a director |
| Mar 28, 2019 | Michiel deZwaan became V.P., Human Resources & CHRO |
| Mar 28, 2019 | Michael J Tokich no longer listed as a director in SEC filings |
| Mar 28, 2019 | Michael B Wood became a director |
| Mar 28, 2019 | Loyal W Wilson became a director |
| Mar 28, 2019 | Kathleen Bardwell became Sr.V. P. & C.C.O. |
| Mar 28, 2019 | Karen L Burton became VP, Controller & CAO |
| Mar 28, 2019 | John Adam Zangerle no longer listed as a director in SEC filings |
| Mar 28, 2019 | Jacqueline B Kosecoff became a director |
| Mar 28, 2019 | Gulam Amjad Khan became Sr. V.P., Procedural Solutions |
| Mar 28, 2019 | Duncan K Nichol became a director |
| Mar 28, 2019 | David B Lewis became a director |
| Mar 28, 2019 | Daniel A Carestio became Sr VP and Chief Operating Off |
| Mar 28, 2019 | Cynthia L Feldmann became a director |
| Mar 28, 2019 | Adrian Vincent Coward became Sr. V P, Healthcare Spec Serv |
| Mar 27, 2019 | Walter M Rosebrough Jr became President & CEO |
| Mar 27, 2019 | Michael J Tokich became a director |
| Mar 27, 2019 | Michael J Tokich became Sr. Vice Pres., CFO |
| Mar 27, 2019 | John Adam Zangerle became a director |
| Mar 27, 2019 | John Adam Zangerle became Sr. VP, Gen Counsel, and Sec. |
Not reported recently (10)
- Jacqueline B Kosecoff · Last reported as a director in an SEC filing dated Aug 12, 2024
- David B Lewis · Last reported as a director in an SEC filing dated Jul 22, 2021
- Walter M Rosebrough Jr · Last reported as President & CEO in an SEC filing dated Nov 10, 2020
- Kathleen Bardwell · Last reported as Sr.V. P. & C.C.O. in an SEC filing dated Jul 2, 2019
- Michiel deZwaan · Last reported as V.P., Human Resources & CHRO in an SEC filing dated Jun 27, 2019
- Loyal W Wilson · Last reported as a director in an SEC filing dated Jun 5, 2019
- Gulam Amjad Khan · Last reported as Sr. V.P., Procedural Solutions in an SEC filing dated Jun 3, 2019
- Adrian Vincent Coward · Last reported as Sr. V P, Healthcare Spec Serv in an SEC filing dated Jun 3, 2019
- Michael B Wood · Last reported as a director in an SEC filing dated May 17, 2019
- Duncan K Nichol · Last reported as a director in an SEC filing dated Mar 28, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
STE Proposed Insider Sales (Form 144)
Latest: 2026-08-18
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $1.9M notice value
· 2 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Sohi Mohsen (1, $957K) · Breeden Richard C (1, $953K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-18 | Breeden Richard C | Director | 4,110 | $953.1K | 2026-08-18 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2026-08-12 | Sohi Mohsen | Director | 4,058 | $956.8K | 2026-08-12 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2026-06-15 | Zangerle John Adam | Officer | 1,419 | $297.0K | 2026-06-15 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-06-05 | Carestio Daniel A | Officer, Director | 1,374 | $291.3K | 2026-06-05 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-06-04 | Carestio Daniel A | Officer, Director | 3,054 | $655.5K | 2026-06-04 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-06-02 | Breeden Richard C | Director | 1,481 | $310.3K | 2026-06-02 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2026-03-05 | FELDMANN CYNTHIA L | Director | 3,098 | $734.9K | 2026-03-05 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2025-11-21 | Madsen Julia | Officer | 5,008 | $1.31M | 2025-11-21 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2025-11-18 | Tamaro Renato | Officer | 5,036 | $1.30M | 2025-11-18 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2025-11-12 | Zangerle John Adam | Officer | 15,000 | $3.98M | 2025-11-11 | Charles Schwab & Co., Inc. | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-04 | Earnings results · Restructuring costs | EDGAR |
| 2026-11-04 | Material agreement · Agreement terminated · New debt obligation | EDGAR |
| 2026-10-13 | Material agreement | EDGAR |
| 2026-08-06 | Shareholder vote results | EDGAR |
| 2026-08-05 | Earnings results · Restructuring costs | EDGAR |
| 2026-05-11 | Earnings results | EDGAR |
| 2026-05-07 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-04-06 | Director or officer change | EDGAR |
| 2026-02-04 | Earnings results | EDGAR |
| 2025-11-05 | Earnings results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-29 | 0001628280-26-039136 | EDGAR |
| 2025-05-29 | 0001757898-25-000005 | EDGAR |
| 2024-05-29 | 0001757898-24-000008 | EDGAR |
| 2023-05-26 | 0001757898-23-000005 | EDGAR |
| 2022-05-31 | 0001757898-22-000011 | EDGAR |
| 2021-05-28 | 0001757898-21-000017 | EDGAR |
| 2020-05-29 | 0001757898-20-000012 | EDGAR |
| 2019-05-30 | 0001757898-19-000005 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-05 | 0001628280-26-070997 | EDGAR |
| 2026-08-07 | 0001628280-26-054830 | EDGAR |
| 2026-02-06 | 0001628280-26-006055 | EDGAR |
| 2025-11-06 | 0001628280-25-050160 | EDGAR |
| 2025-08-07 | 0001757898-25-000008 | EDGAR |
| 2025-02-07 | 0001757898-25-000002 | EDGAR |
| 2024-11-07 | 0001757898-24-000018 | EDGAR |
| 2024-08-08 | 0001757898-24-000016 | EDGAR |
| 2024-02-08 | 0001757898-24-000002 | EDGAR |
| 2023-11-07 | 0001757898-23-000013 | EDGAR |
ETF Holders
205 ETFs hold STE
25 shown · $4.31B total exposure · 0.07% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.03% | $649.0M | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.03% | $537.8M | — | 2026-09-30 |
| 3 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.20% | $438.5M | — | 2026-09-30 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.04% | $336.7M | $871.7B | 2026-11-09 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.04% | $307.2M | $791.9B | 2026-11-09 |
| 6 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.23% | $241.2M | — | 2026-11-09 |
| 7 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.08% | $195.1M | — | 2026-09-30 |
| 8 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.03% | $189.1M | — | 2026-09-30 |
| 9 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.37% | $185.3M | $50.5B | 2026-11-09 |
| 10 | SDY State Street® SPDR® S&P® Dividend ETF | SPDR (State Street) | 0.66% | $148.7M | $22.6B | 2026-11-09 |
| 11 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 3.08% | $126.5M | $4.1B | 2026-11-09 |
| 12 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.04% | $124.4M | — | 2026-09-30 |
| 13 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 0.09% | $115.8M | — | 2026-09-30 |
| 14 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.18% | $107.5M | $58.7B | 2026-11-09 |
| 15 | VOT Vanguard Morningstar Mid-Cap Growth ETF | Vanguard | 0.24% | $80.4M | — | 2026-09-30 |
| 16 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.04% | $70.6M | $183.2B | 2026-11-09 |
| 17 | ESGU iShares ESG Aware MSCI USA ETF | iShares (BlackRock) | 0.39% | $69.4M | $17.5B | 2026-11-09 |
| 18 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.17% | $63.9M | — | 2026-09-30 |
| 19 | VHT Vanguard Health Care ETF | Vanguard | 0.29% | $62.5M | — | 2026-09-30 |
| 20 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.07% | $61.1M | — | 2026-11-09 |
| 21 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.07% | $55.5M | $84.7B | 2026-11-09 |
| 22 | SPHQ Invesco S&P 500 Quality ETF | Invesco | 0.22% | $41.6M | — | 2026-11-09 |
| 23 | FVD First Trust Value Line® Dividend Index Fund | First Trust | 0.45% | $36.9M | $8.2B | 2026-11-09 |
| 24 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.24% | $36.1M | $15.1B | 2026-11-09 |
| 25 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.03% | $33.2M | $95.3B | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
30.54
TTM Diluted EPS
$8.42
TTM Revenue
$6.17B
TTM Net Income
$826.90M
TTM Op. Cash Flow
$1.29B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '27 | 2026-09-30 | $1.59B | $213.70M | $2.19 | $289.00M |
| Q4 '26 | 2026-03-31 | $1.59B | $220.20M | $2.24 | $335.50M |
| Q3 '26 | 2025-12-31 | $1.50B | $192.90M | $1.96 | $298.20M |
| Q2 '26 | 2025-09-30 | $1.46B | $191.90M | $1.94 | $287.80M |
| Q1 '26 | 2025-06-30 | $1.39B | $177.40M | $1.79 | $420.00M |
| Q4 '25 | 2025-03-31 | $1.48B | $145.60M | $1.47 | $260.90M |
| Q3 '25 | 2024-12-31 | $1.37B | $173.50M | $1.75 | $332.70M |
| Q2 '25 | 2024-09-30 | $1.33B | $150.00M | $1.51 | $250.80M |
| Q1 '25 | 2024-06-30 | $1.28B | $145.40M | $1.46 | $303.70M |
| Q4 '24 | 2024-03-31 | $1.42B | $-1.38M | $-0.01 | $254.81M |
| Q3 '24 | 2023-12-31 | $1.30B | $140.74M | $1.42 | $291.24M |
| Q2 '24 | 2023-09-30 | $1.24B | $115.32M | $1.16 | $146.09M |
Q2 2027 • period ending 2026-09-30 • filed 2026-11-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
30.54
P/B
3.53
P/S
4.28
EV/EBITDA
16.80
EV/Sales
4.51
ROE
10.9%
ROA
7.3%
Div Yield
1.01%
FCF Yield
5.28%
Debt/Equity
0.25
Current Ratio
—
Market Cap
$25.38B
as of 2026-11-10
STE vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ABT Abbott Laboratories | $191.4B | 40.9 | +10.0% | −11.1% | 19 |
| ISRG Intuitive Surgical Inc. | $159.7B | 54.4 | +20.5% | −19.9% | 16 |
| MDT Medtronic plc | $131.5B | 25.0 | +9.8% | +5.8% | 59 |
| SYK Stryker Corporation | $124.0B | 34.5 | +7.9% | −6.9% | 32 |
| BSX Boston Scientific Corp. | $63.8B | 18.9 | +8.9% | −52.8% | 7 |
| BDX Becton, Dickinson and Co. | $58.6B | 53.8 | +6.4% | +9.1% | 31 |
| GEHC GE HealthCare Technologies Inc. Common S | $38.0B | 17.6 | +6.9% | +1.0% | 19 |
| RMD ResMed Inc. | $33.2B | 21.3 | +9.0% | −4.4% | 17 |
| STE STERIS plc | $25.0B | 30.5 | +8.1% | +2.8% | 33 |
| Peer median | $93.9B | 29.8 | +8.9% | −5.6% | 19 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.40M
SI % of Float
2.47%
Days to Cover
3.56
Short Vol Ratio
68.2%
Free Float
97.24M
Float %
99.7%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-24